FDA slaps a hold on KalVista's PhII study of an HAE drug, raising a red flag on preclinical results
Investors on board for KalVista’s roller coaster ride of stock swings are in for some new drama. Two months after the biotech reported positive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
